CHICAGO, April 29, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication ...

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear ...

SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas of disease. The companies said they will work together to train ...

Tempus AI announced a collaboration with AstraZeneca and Pathos AI. The deal will generate $200 million for Tempus AI in data licensing and model development fees. Tempus AI has invested heavily ...

In the last three months, 9 analysts have published ratings on Tempus AI TEM, offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ...

Gifting allows recipients to access the article for free. Tempus AI said it will work with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology that can gather biological ...

The TIME Precision Network is a newly-formed group of investigators across TIME’s provider site network dedicated to supporting Phase I trials Tempus AI, Inc. (NASDAQ: TEM), a technology company ...